Our results suggest that risk profiling on the basis of PRSs may identify male carriers of BRCA1/2 mutations at both sufficiently reduced or increased risk of breast or prostate cancer, with implications for their clinical management. The gene discussed is BRCA1; the disease is Familial prostate cancer.